AVITA Medical to demonstrate cost-effectiveness of RECELL® for burn treatment
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Regenerative medicine company, AVITA Medical (ASX:AVH | OTCQX:AVMXY), today revealed that it will be presenting an economic model demonstrating the cost benefit of its RECELL® treatment at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting.
The abstract for presentation, titled ‘Inpatient Cost of Acute Care for Severe Burn Patients: Validation of Economic Model for Adults and Children’, highlights the cost-effectiveness of RECELL in contrast to the standard of care for treatment of severe burns.
The meeting will be held on May 21 in Baltimore, Maryland.
Burns require costly care due to the need for complex and individualised treatment. RECELL is a medical device designed to facilitate skin regeneration while minimising the amount of skin harvested at the time of surgery. Reduction in donor site skin requirements has important benefits from both clinical and health economic perspectives.
AVH CEO, Dr Michael Perry, said: “The model demonstrates the potential of RECELL to improve patient care while at the same time reducing the overall cost of treating patients.”
“One of the strengths of this model is that it may be tailored to patient populations relevant to individual hospitals, healthcare systems, and other organizations engaged in the treatment of burn patients around the world.”
“This externally validated model will allow us to approach hospital value and analysis committees and payers with a strong economic package that supports the cost savings that may be achieved with the use of RECELL,” Perry added.
Of course, it should be noted that AVH is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.
The model was developed by AVH, IQVIATM and the Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response, within the US Department of Health and Human Services.
Funding provided by BARDA to support the development of RECELL has included support of the health economic model.
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multi-stakeholder non-profit dedicated to advancing HEOR excellence to improve decision making for health globally. It is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
ISPOR’s Annual International Meeting is an international forum highlighting research and methods that advance the quality and value of health care decisions.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
